Patents by Inventor Leif Nørskov-Lauritsen

Leif Nørskov-Lauritsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20200306382
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 1, 2020
    Applicant: Novo Nordisk HealthCare AG
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20200102568
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 2, 2020
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20190203213
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20180221501
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20170239362
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 24, 2017
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth hormones with prolonged in-vivo efficacy
    Patent number: 9695226
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 4, 2017
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Growth Hormone Compounds
    Publication number: 20160017017
    Abstract: The invention relates to growth hormone compounds with a long plasma half-life obtained by Fc linkage. An increased half-life is an advantage allowing a less frequent or low dosage administration of therapeutic. The invention further relates to methods of producing such compound including expression vectors for heterologous expression.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: NOVO NORDISK HEALTHCARE AG
    Inventors: Xin Zhao, Peter Thygesen, Nils Langeland Johansen, Leif Noerskov-Lauritsen
  • Stable growth hormone compounds resistant to proteolytic degradation
    Patent number: 9211342
    Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: December 15, 2015
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Helle Demuth, Christine Brunn Schioedt, Leif Noerskov-Lauritsen, Jianhe Chen, Peter Thygesen
  • Fatty Acid Acylated Amino Acids for Growth Hormone Delivery
    Publication number: 20150250882
    Abstract: The present invention relates to growth hormone compositions comprising a fatty acid acylated amino acids (FA-aa's), which may be used in pharmaceutical compositions such as pharmaceutical compositions for oral administration of growth hormone.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 10, 2015
    Inventors: Mats Reslow, Leif Noerskov-Lauritsen, Heidi Westh Bagger, Christine Bruun Schioedt
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20140329750
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Growth hormones with prolonged in-vivo efficacy
    Patent number: 8779109
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 15, 2014
    Assignee: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20140107324
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Stable growth hormone compounds resistant to proteolytic degradation
    Patent number: 8513192
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 20, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
  • GROWTH HORMONE CONJUGATES
    Publication number: 20130143815
    Abstract: The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.
    Type: Application
    Filed: July 15, 2011
    Publication date: June 6, 2013
    Applicant: NOVO NORDISK HEALTH CARE AG
    Inventors: Henrik Sune Andersen, Kjeld Madsen, Helle Demuth, Christine Bruun Schioedt, Leif Noerskov-Lauritsen, Peter Thygesen, Carsten Behrens, Mette Guldbrandt
  • STABLE GROWTH HORMONE COMPOUNDS
    Publication number: 20130040883
    Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.
    Type: Application
    Filed: January 24, 2011
    Publication date: February 14, 2013
    Applicant: Novo Nordisk HealthCare AG
    Inventors: Helle Demuth, Christine Brunn Schioedt, Leif Noerskov-Lauritsen, Jianhe Chen, Peter Thygesen
  • Growth Hormones With Prolonged In-Vivo Efficacy
    Publication number: 20120309944
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Application
    Filed: January 24, 2011
    Publication date: December 6, 2012
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • STABLE GROWTH HORMONE COMPOUNDS
    Publication number: 20110306548
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Application
    Filed: January 22, 2010
    Publication date: December 15, 2011
    Applicant: Novo Nordisk Health Care AG
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
  • Novel Prolactin Compounds
    Publication number: 20100292444
    Abstract: The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation.
    Type: Application
    Filed: July 3, 2008
    Publication date: November 18, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jens Breinholt, Per Franklin Nielsen, Leif Christensen, Leif Nørskov-Lauritsen, Anders Swensson
  • Transglutaminase Variants with Improved Specificity
    Publication number: 20100099610
    Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 22, 2010
    Inventors: Sean Hu, Xao Zin, Wang Jianhua, Chihchuan Chang, Leif Nørskov-Lauritsen, Jing Su
  • Transglutaminase Variants with Improved Specificity
    Publication number: 20100087371
    Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 8, 2010
    Inventors: Sean Hu, Zhao Xin, Wang Jianhua, Chihchuan Chang, Leif Nørskov-Lauritsen, Jing Su